Evidence map›Paper›PMID 41260636›Full record

ReviewJournal of the American Board of Family Medicine : JABFM2025

National Drug Shortages: Remedial Executive and Legislative Initiatives.

Eli Y Adashi, Daniel P O'Mahony, I Glenn Cohen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Board of Family Medicine : JABFM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eli Y AdashiFrom the Brown University; Brown University Library; Harvard Law School; and Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University (EYA, DPO, IGC). Eli_Adashi@brown.edu.
Daniel P O'MahonyFrom the Brown University; Brown University Library; Harvard Law School; and Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University (EYA, DPO, IGC).
I Glenn CohenFrom the Brown University; Brown University Library; Harvard Law School; and Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University (EYA, DPO, IGC).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication shortages constitute an ongoing threat to patient care across the United States and affect nearly every aspect of health care. National drug shortages have been a recurring challenge of the US health care system but were markedly aggravated during the COVID-19 pandemic. Federal executive and legislative efforts to bolster the resiliency of the pharmaceutical supply chain have thus far fallen short. This Commentary reviews the leading executive and legislative initiatives proposed during the 118

Indexed as

Health PolicyPharmaceutical PreparationsUnited StatesPharmaceutical PreparationsAccess to CareHealth PolicyMedication SystemsPharmaceutical Policy

Identifiers

PMID41260636
PMCPMC12978594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.